ランキング価格はじめての方へ
  1. 米国企業
  2. Applied Therapeutics, Inc.

Applied Therapeutics, Inc.APLT

時価総額
$8.5億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net loss-46-94-106-82-120
Share-based Compensation681197
Options Issued In Lieu Of Bonus---0-
Amortization of insurance premium-3442
Amortization of insurance premium-3442
Amortization of operating lease right-of-use assets--000
Amortization of operating lease right-of-use assets--000
Amortization of leasehold improvements---00
Amortization of leasehold improvements---00
Change in operating lease liability---0-0-0
Change in operating lease liability---0-0-0
Fair Value Adjustment of Warrants---057
Fair Value Adjustment of Warrants---057
Financed insurance premium-3432
Prepaid expenses6-22-0-2
Accounts payable6-89-5-3
Accrued expenses and other current liabilities314-3-21
Other liabilities---00
Financed insurance premium-3432
Prepaid expenses6-22-0-2
Accounts payable6-89-5-3
Accrued expenses and other current liabilities314-3-21
Other liabilities---00
Net cash used in operating activities-36-78-91-78-55
Net cash used in operating activities-36-78-91-78-55
Purchase of available-for-sale securities2013512264-
Proceeds from sale of available-for-sale securities-176-5
Proceeds from maturities of available-for-sale securities-98128779
Net cash provided by investing activities-20-19121314
Proceeds From Issuance Of Shares And Pre Funded Warrants---28-
Proceeds from issuance of common stock, pre-funded warrants and reissuance of treasury stock, net of issuance costs----65
Proceeds from financed insurance premium-3432
Proceeds from financed insurance premium-3432
Repayments of short-term borrowings-2532
Repayments of short-term borrowings-2532
Proceeds from Stock Options Exercised02100
Proceeds from Stock Options Exercised02100
Exercise of Warrants--0-10
Exercise of Warrants--0-10
Net cash provided by financing activities56136752875
Net cash provided by financing activities56136752875
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS039-4-3733
Initial measurement of warrant liability---22-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net-----0
Conversion Of Warrant Liability To Equity---117
Offering costs in accrued expenses----0
Warrant Liability, Reclassification to Equity---7-
Conversion Of Warrant Liability To Equity---117
Marketable Securities, Unrealized Gain (Loss)--000-0
Warrant Liability, Reclassification to Equity---7-